BamSEC and AlphaSense Join Forces
Learn More

PhaseBio Pharmaceuticals Inc – Material Contracts

Formerly NASDAQ: PHAS
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 8-K 6 pages Plan Support and Settlement Agreement
12/34/56
EX-10.2
from 8-K 43 pages Material contract
12/34/56
EX-10.1
from 8-K 17 pages Material contract
12/34/56
EX-10.1
from 8-K 83 pages Material contract
12/34/56
EX-10.1
from 10-Q 6 pages PhaseBio Pharmaceuticals, Inc. Rsu Award Grant Notice
12/34/56
EX-10.2
from 10-Q 6 pages PhaseBio Pharmaceuticals, Inc. Rsu Award Grant Notice
12/34/56
EX-10.1
from 10-Q 6 pages PhaseBio Pharmaceuticals, Inc. Rsu Award Grant Notice
12/34/56
EX-10.25
from 10-K 1 page Amendment No. 1 to Master Services Agreement
12/34/56
EX-10.9
from 10-K 17 pages PhaseBio Pharmaceuticals, Inc. Severance Benefit Plan Amended and Restated as of March 23, 2022
12/34/56
EX-10.7
from 10-K 2 pages PhaseBio Pharmaceuticals, Inc. Non-Employee Director Compensation Policy as Amended February 24, 2022
12/34/56
EX-10.6
from 10-K 6 pages PhaseBio Pharmaceuticals, Inc. Rsu Award Grant Notice
12/34/56
EX-10.3
from 10-K 6 pages PhaseBio Pharmaceuticals, Inc. Rsu Award Grant Notice
12/34/56
EX-10.2
from 10-Q 38 pages PhaseBio Pharmaceuticals, Inc. $55,000,000 Shares Common Stock ($0.001 Par Value) Equity Distribution Agreement
12/34/56
EX-10.1
from 10-Q 24 pages PhaseBio Pharmaceuticals, Inc. 2018 Equity Incentive Plan Adopted by the Board of Directors: October 4, 2018 Approved by the Stockholders: October 4, 2018 Ipo Date: October 17, 2018 Amended by the Board of Directors: April 22, 2021 Approved by the Stockholders: June 3, 2021
12/34/56
EX-10.2
from 10-Q 16 pages Acknowledgment of Grant of a Sublicense in Accordance With the License Agreement Between Medimmune Limited and PhaseBio Pharmaceuticals, Inc. and Related Options
12/34/56
EX-10.1
from 10-Q 117 pages License Agreement Between Alfasigma S.P.A. and PhaseBio Pharmaceuticals, Inc. Dated as of June 16, 2021
12/34/56
EX-10.2
from 10-Q 38 pages Certain Information Has Been Excluded From This Agreement (Indicated by “[***]”) Because Such Information Is Both Not Material and the Type That the Registrant Treats as Private or Confidential. Supply Agreement
12/34/56
EX-10.3
from 10-K 2 pages PhaseBio Pharmaceuticals, Inc. Non-Employee Director Compensation Policy as Amended February 9, 2021
12/34/56
EX-10.23
from 10-K 60 pages Agreement
12/34/56
EX-10.22
from 10-K 11 pages Certain Information Has Been Excluded From This Agreement (Indicated by “[***]”) Because Such Information (I) Is Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed. Program Transfer Agreement
12/34/56